Diagnostic Test: blood drawing in healthy controls ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 1 |
65. Primary immunodeficiency
Clinical trials : 482 / Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00909363 (ClinicalTrials.gov) | June 2009 | 27/5/2009 | Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients | Effects Of Eltrombopag On Thrombocytopenia, Platelet Function and Bleeding In Patients With Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia. | Wiskott-Aldrich Syndrome;Thrombocytopenia;Bleeding | Drug: Promacta;Diagnostic Test: blood drawing in patients with WAS;Diagnostic Test: blood drawing in healthy controls | Weill Medical College of Cornell University | Novartis Pharmaceuticals | Terminated | 3 Months | 80 Years | Male | 24 | Phase 2 | United States |